Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The GUMMMy Bear Squad touting Gum Tech (NASDAQ: GUMM) -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (158)	3/9/2000 1:23:00 AM
From: Phil(bullrider)	Respond to of 207

Dan, Thanks for a response in 1000 words or less. Now, The stock market isn't always rational and stocks can trade to unreasonable prices in the short term. Who would have thought that investors would push VPHM from $5 to $110 or CIEN from $8 to $170? The market is entirely nuts at times and it is possible that GUMM could trade to 50 or 60 if the clinical studies are published in a reputable journal and backed by a reputable researcher. The short interest in GUMM was up to 1.2 million shares as of February and I suspect that it is even higher now. If good news is released and John Q Public gets behind the stock, anyone that is short could get screwed royally. The question is at what price would people offer to sell stock if short and new longs are jumping over each other to buy the stock. I'm not saying this to scare anyone. I'm saying it in all honesty and sincerely hope that nobody gets hurt too badly IF it happens. I don't know for a fact that it will happen, but I suspect that it will. Where else are the clinical results that were due in October 99? Let's review your paragraph. First: The stock market isn't always rational and stocks can trade to unreasonable prices in the short term. Who would have thought that investors would push VPHM from $5 to $110 or CIEN from $8 to $170? As you know (I hope), stock prices rise and fall on hope of a ROI. Tech stocks seem to offer more of a ROI than most, so they rise and fall more than most. I can see how you can use VPHM as a comparison to GUMM, even though I don't remotely consider GUMM to be a "biotech". But CIEN? What does a telecom company have to do with a chewing gum company? Check DGIL for a recent mover. So what? The market is entirely nuts at times and it is possible that GUMM could trade to 50 or 60 if the clinical studies are published in a reputable journal and backed by a reputable researcher. This is the same claim that has been made many times. IMHO, there will be no study published by any reputable journal. GUMM screwed up the best chance they had, and it was a second rate publication at best. If good news is released and John Q Public gets behind the stock, anyone that is short could get screwed royally. I am only short a very small percentage of my portfolio. This stock could go to 100 and I would not be hurt. Other than my feelings, for making a wrong call. I don't believe anyone that uses shorting as a tool risks more than a small percentage in any one position. You shills are the only ones that seem to risk big positions. There are a lot of ifs, ands, or buts in your post, but I feel I am becoming too windy, like most of your posts. You can consider this my last post on the subject, since all of the facts have been stated many, many, many times. Have fun, Phil

To: DanZ who wrote (158)	3/9/2000 7:50:00 AM
From: Mad2	Read Replies (1) \| Respond to of 207

Dan, Thanks for your view on revenue. Have you asked GUMM what their order book is for the 1st qtr? As stocks get overbought when going up, they tend to get oversold on the way down. I do see GUMM as being volatile until direction is clear. If in fact revenues will be down in the 1st qtr I think GUMM is in deep trouble, particularly because the distribution and retail channel in the USA is now filled. Now that GUMM has revenue, the stock will begin to trade based on results, and the direction those results point. Mad2